Think Bioscience Secures Oversubscribed $55M Series A for Synthetic Biology Drug Discovery Platform

Boulder, Colorado-based synthetic biology pioneer Think Bioscience has successfully closed a $55 million oversubscribed Series A funding round, attracting elite investors confident in its ability to transform drug discovery for historically undruggable protein targets. The financing was co-led by Regeneron Ventures and Innovation Endeavors, with significant participation from Janus Henderson Investors. Additional new investors include CE-Ventures (the venture arm of UAE-based Crescent Enterprises), MBX Capital, T.A. Springer, and YK Bioventures. Returning backers AV8 Ventures, CU Innovations, and Buff Gold Ventures also reinvested, reflecting sustained belief in the company's scientific execution and platform momentum.

The oversubscription, which exceeded the original target, provides Think Bioscience with an extended financial runway to execute on multiple fronts during a period of heightened scrutiny in biotech venture funding. The investor syndicate combines strategic pharmaceutical expertise from Regeneron, technology-focused venture capital from Innovation Endeavors, and global institutional capital, signaling broad validation across multiple stakeholder categories.

Synthetic biology redefines target identification. Think Bioscience’s core innovation lies in its proprietary platform, which leverages engineered biological systems to reveal cryptic or transient binding pockets on protein surfaces. Traditional small-molecule drug discovery depends on stable, well-defined pockets identified through X-ray crystallography or computational modeling. However, the majority of disease-relevant proteins, including key oncology drivers, neurodegeneration targets, and fibrosis mediators, lack such accessible sites, rendering them “undruggable” despite genomic advances that identify them as causal biology.

By systematically exposing these hidden vulnerabilities, Think Bioscience enables chemists to design high-affinity small molecules against targets previously dismissed as infeasible. The approach mirrors breakthroughs in computational biology, such as AlphaFold, but extends into experimental validation, bridging the gap between structure prediction and actionable chemistry.

Pipeline prioritization and Noonan syndrome focus. Series A proceeds will advance the company’s lead program targeting Noonan syndrome, a multisystem genetic disorder affecting approximately one in 2,500 newborns. The condition is characterized by congenital heart defects, short stature, facial dysmorphology, and developmental challenges. Noonan syndrome currently lacks therapies that address its root molecular causes, primarily gain-of-function mutations in the RAS/MAPK signaling pathway. Success in this indication could establish proof of concept for the platform across broader RASopathy indications and other undruggable targets.

Funds will also expand the discovery engine's throughput, hire key talent in computational biology and medicinal chemistry, and initiate additional pipeline programs in oncology and rare diseases where protein conformational dynamics have blocked progress.

Strategic positioning in the 2026 biotech landscape. The financing arrives amid renewed venture optimism following the capital contraction of 2025. Regeneron’s participation carries particular weight, given the pharma giant’s track record of backing platform companies with scalable, differentiated approaches to high-value biology. Innovation Endeavors’ involvement, known for early bets on computational drug discovery, further validates the synthetic biology thesis.

For Think Bioscience, the round marks a transition from platform validation to clinical execution. With $55 million committed and investor confidence reflected in the oversubscription, the company enters 2026 positioned to deliver human data that could catalyze Series B discussions and strategic pharma partnerships.